Rimegepant for the acute and preventive treatment of migraine : a narrative review of the evidence
(2024) In Expert Review of Neurotherapeutics 24(12). p.1141-1155- Abstract
Introduction: Rimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine. Areas covered: A brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant. Expert opinion: Several... (More)
Introduction: Rimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine. Areas covered: A brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant. Expert opinion: Several clinical trials established rimegepant as a safe and effective treatment (acute and preventive) of migraine in adults. There are few head-to-head studies with other migraine treatments to determine relative efficacy. However, the favorable safety profile of rimegepant makes it appropriate for many patients, particularly those with contraindication, intolerance, or inadequate response to other classes of standard-of-care migraine treatments. Additional studies on the efficacy and cost-effectiveness relative to other treatments may further define the role of rimegepant in migraine treatment.
(Less)
- author
- Edvinsson, Lars LU
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acute, calcitonin gene-related peptide, migraine, preventive, review, rimegepant
- in
- Expert Review of Neurotherapeutics
- volume
- 24
- issue
- 12
- pages
- 15 pages
- publisher
- Future Drugs Ltd
- external identifiers
-
- scopus:85211123774
- pmid:39620902
- ISSN
- 1473-7175
- DOI
- 10.1080/14737175.2024.2434079
- language
- English
- LU publication?
- yes
- id
- 157312d2-c8af-4009-b68a-e8adf3bdebbf
- date added to LUP
- 2025-01-28 11:28:48
- date last changed
- 2025-07-16 00:50:11
@article{157312d2-c8af-4009-b68a-e8adf3bdebbf,
abstract = {{<p>Introduction: Rimegepant is an oral small-molecule calcitonin gene-related peptide receptor antagonist approved in several countries for acute treatment of migraine and preventive treatment of episodic migraine in adults. This review summarizes the evidence, published to date, for the use of rimegepant as an acute or preventive treatment of migraine. Areas covered: A brief overview of migraine, the pharmacokinetics of rimegepant, and the mechanism of action of rimegepant are provided. Evidence evaluating rimegepant as an acute or preventive treatment of migraine is then summarized in more detail, based on a literature search for full-length publications related to clinical or real-world use of rimegepant. Expert opinion: Several clinical trials established rimegepant as a safe and effective treatment (acute and preventive) of migraine in adults. There are few head-to-head studies with other migraine treatments to determine relative efficacy. However, the favorable safety profile of rimegepant makes it appropriate for many patients, particularly those with contraindication, intolerance, or inadequate response to other classes of standard-of-care migraine treatments. Additional studies on the efficacy and cost-effectiveness relative to other treatments may further define the role of rimegepant in migraine treatment.</p>}},
author = {{Edvinsson, Lars}},
issn = {{1473-7175}},
keywords = {{Acute; calcitonin gene-related peptide; migraine; preventive; review; rimegepant}},
language = {{eng}},
number = {{12}},
pages = {{1141--1155}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Neurotherapeutics}},
title = {{Rimegepant for the acute and preventive treatment of migraine : a narrative review of the evidence}},
url = {{http://dx.doi.org/10.1080/14737175.2024.2434079}},
doi = {{10.1080/14737175.2024.2434079}},
volume = {{24}},
year = {{2024}},
}